Japan To Lower Price Caps On Key Prescription Drugs
This article was originally published in PharmAsia News
Executive Summary
Japan plans new price caps on prescription drugs in April, lowered by an average of 5.2 percent. Some of the most popular drugs produced by major drug makers face an even steeper reduction in the maximum price allowed, by 10.1 percent. The new caps are expected to cause more pharmaceutical makers to shift their focus from marketing drugs in Japan to other countries. Among drugs facing the greatest price reduction are those in a new generation of medicines to lower blood pressure, including Takeda's Blopress (candesartan cilexetil), Astellas' Micardis (telmisartan) and Daiichi Sankyo's Olmetec (olmesartan). (Click here for more - a subscription may be required
You may also be interested in...
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.